Evidence map›Paper›PMID 41580532›Full record

ArticleNPJ precision oncology2026

Exploring translational relevance of baseline and longitudinal metabolic profiling in the blood of ovarian cancer patients.

Alexander Max Funk, Lisa Freitag, Franziska Maria Schwarz, Theresa Link, Sophie Jonas, Pauline Wimberger, Mareike Brieske, Anna Klimova, Triantafyllos Chavakis, Peter Mirtschink and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexander Max Funk *Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Fetscherstrasse 74, Dresden, Germany.
Lisa Freitag *National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Franziska Maria SchwarzNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Theresa LinkNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Sophie JonasInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Fetscherstrasse 74, Dresden, Germany.
Pauline WimbergerNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Mareike BrieskeNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Anna KlimovaNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Triantafyllos ChavakisInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Fetscherstrasse 74, Dresden, Germany.
Peter MirtschinkInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Fetscherstrasse 74, Dresden, Germany.
Jan Dominik KuhlmannNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. jan.kuhlmann@uniklinikum-dresden.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted blood-based metabolomic profiling in ovarian cancer and determined its clinical relevance. NMR spectroscopy was performed on a total of n = 760 longitudinal plasma samples from n = 292 ovarian cancer patients, probing for n = 39 metabolites. At primary diagnosis, we revealed two distinguishable signatures, representing blood-based surrogates for a continuum of two metabolic states in ovarian cancer. These signatures shaped two subgroups of patients with differential surgical outcome and relapse risk (HR = 1.605, 95%CI:1.11-2.32, p = 0.009). Deconvolution of the metabolomic signatures identified acetoacetate, 3-hydroxybutyrate and alanine among the most relevant signature-determining metabolites. The acetoacetate

Identifiers

PMID41580532
PMCPMC12852794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.